[15]. Linardou H, Dahabreh I J, Kanaloupiti D, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer[J]. Lance...
Sotorasib与程序性死亡[蛋白]配体-1(programmed death ligand-1,PD-L1)抑制剂联合治疗KRASG12C突变的非小细胞肺癌(non-small cell lung cancer,NSCLC)的CodeBreak100/101研究结果显示,联用阿替利珠单抗后的安全性要明显高于联用帕博利珠单抗,同时sotora...
3.2.3 非小细胞肺癌肺癌是一种常见的恶性肿瘤,可分为非小细胞肺癌(non-small cell lung cancer,NSCLC) 和小细胞肺癌(small cell lung cancer,SCLC), 其中 NSCLC 占肺癌的 80% ~ 85%[71]。尽管近年对肺癌免疫治疗及靶向药物的研究取得一定进展,但...
Human non-small cell lung cancer (NSCLC) cell lines with inactivated LKB1 and KRAS mutations are sensitive to MEK inhibitioncolorectal cancerdisease-free survivaloverall survivalprogression-free survivalsurrogate endpointsDespite significant advances in the treatment of hematological malignancies over the ...
[3]Wouter W. Mellema, et al.Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer.Lung Cancer. 2015 Nov;90(2):249-54. [4]Anna Ketal.Survival outcome according to KRAS mutation status in newly diagnos...
[3]Wouter W. Mellema, et al.Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer.Lung Cancer. 2015 Nov;90(2):249-54. [4]Anna Ketal.Survival outcome according to KRAS mutation status in newly diagnos...
最为典型的是非小细胞肺癌(Non-Small Cell Lung Cancer,简称NSCLC)。在NSCLC患者中,约有10%-15%的患者存在EGFR突变。这种突变导致EGFR持续活化,进而推动癌细胞的异常快速生长与扩散。此外,乳腺癌、结肠癌、胶质母细胞瘤等也与EGFR的异常活性有关。 KRAS ...
First-Line Non-Small Cell Lung Cancer (NSCLC). Retrieved October 23, 2023, from https://ir.mirati.com/press-releases/press-release-details/2023/Mirati-Presents-Late-Breaking-Results-Evaluating-the-Combination-of-Adagrasib-and-Pembrolizumab-in-First-Line-Non-Small-Cell-Lung-Cancer-NSCLC/default....
[5]Marabese M, Ganzinelli M, Garassino MC, et al. KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy [J]. Oncotarget. 2015 Oct 20;6(32):34014-22. [6]Muñoz-Maldonado C, Zimmer Y, Medová M. A Comparative An...
As of 1 January 2024, 153 patients had received single-agent divarasib (non-small cell lung cancer [NSCLC]: n=65; colorectal cancer [CRC]: n=61; other solid tumors [OST]: n=27). Median treatment duration was 9.57...